Compare · ABT vs PAHC
ABT vs PAHC
Side-by-side comparison of Abbott Laboratories (ABT) and Phibro Animal Health Corporation (PAHC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PAHC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $221.65B, about 295.8x PAHC ($749.3M).
- Over the past year, ABT is down 29.7% and PAHC is up 199.3% - PAHC leads by 229.0 points.
- ABT has been more active in the news (8 items in the past 4 weeks vs 5 for PAHC).
- ABT has more recent analyst coverage (25 ratings vs 11 for PAHC).
- Company
- Abbott Laboratories
- Phibro Animal Health Corporation
- Price
- $91.15-1.41%
- $55.20+1.02%
- Market cap
- $221.65B
- $749.3M
- 1M return
- -13.05%
- -3.23%
- 1Y return
- -29.66%
- +199.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 11
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Phibro Animal Health Corporation
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Latest ABT
- Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
- SEC Form S-8 filed by Abbott Laboratories
- Abbott Labs downgraded by Daiwa Securities with a new price target
- Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
- New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
- SEC Form 4 filed by Stratton John G
- SEC Form 4 filed by Roman Michael F
Latest PAHC
- President and CEO Bendheim Jack sold $1,157,091 worth of shares (21,120 units at $54.79) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Bendheim Jack
- Citigroup initiated coverage on Phibro Animal Health with a new price target
- Phibro Animal Health Corporation filed SEC Form 8-K: Leadership Update
- SEC Form SCHEDULE 13G filed by Phibro Animal Health Corporation
- SEC Form 4 filed by Bendheim Jack
- Amendment: SEC Form SCHEDULE 13G/A filed by Phibro Animal Health Corporation
- SEC Form 4 filed by Bendheim Jack
- SEC Form 4 filed by Bendheim Jack
- President and CEO Bendheim Jack converted options into 100,000 shares and sold $258,245 worth of shares (5,280 units at $48.91) (SEC Form 4)